CSF2 and hematologic disorder: A recent study of 15 pediatric patients with hematological malignancies and refractory invasive fungal diseases as well as a literature review of 50 patients demonstrated a favorable therapeutic response rate to the administration of GM-CSF when added to antifungal therapy [206].